NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

Qiagen N.V. (QGEN) Stock Analysis

Qiagen N.V. (QGEN) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

QGEN

$43.47

−$0.39 (−0.89%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QGEN with… →

QGEN Key Statistics

As of Sep 4, 2026
Trading
Open
$43.19
Previous Close
$43.86
Day's Range
42.79–43.66
52-Week Range
32.53–57.82
Volume
1.92M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.63
Valuation
Market Cap
$8.98B
P/E Ratio
22.07
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.66
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.17
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.27
EPS (ttm)Profit attributable to each share over the last twelve months.
1.97
Financials (FY)
Revenue (FY)
$2.09B+5.65%
Net Income (FY)
$424.88M+408.28%
Profit marginThe share of revenue left as profit after all costs and taxes.
19.49%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
206.50M
1-Year Return
−6.76%
Dividend and dates
Dividend
$0.35+0.80%
Ex-Dividend Date
July 7, 2026
Earnings Date
November 4, 2026
Avg Volume
2.90M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QGEN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.46%
2025+1.51%
2024+2.43%
2023−12.91%
2022−10.27%
2021+5.17%
2020+56.36%
2019−1.89%
2018+11.38%
2017+10.52%
2016 (partial year)+5.50%

As of September 4, 2026.

QGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.09B$424.88M20.3%
2024$1.98B$83.59M4.2%
2023$1.97B$341.30M17.4%
2022$2.14B$423.21M19.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.09B$1.30B$520.31M$424.88M20.3%
2024$1.98B$967.35M$199.90M$83.59M4.2%
2023$1.97B$1.23B$445.25M$341.30M17.4%
2022$2.14B$1.38B$576.23M$423.21M19.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QGEN Dividend History

$0.25−81.6% vs 2024

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2026*$0.351—
2025$0.251−81.6%
2024$1.361—
2017$1.151—

Most recent payment: $0.35 per share, ex-dividend July 7, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

QGEN Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricQGENDiagnostics & Research medianvs median
P/E22.0733.0833% below
P/S ratio4.274.9914% below
Profit margin19.49%0.00%19.5 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Qiagen N.V. (QGEN) is capitalised at $8.98B on the latest close. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 5,500.

Over the past 52 weeks the price has ranged from $32.53 to $57.82. The most recent close on file for QGEN is $43.47, dated September 4, 2026. That is −$0.39 (−0.89%) against the previous close. The latest close sits 33.63% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.09B. Against the prior fiscal year total of $1.98B, that is a change of +5.65%. Net income for the same year was $424.88M. That is +408.28% against the prior fiscal year. The reported profit margin is 19.49%. That is 19.5 percentage points above the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to 1.97.

Across the 4 fiscal years on file, revenue moves from $2.14B in 2022 to $2.09B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 22.07 times earnings. That is 33.28% below the Diagnostics & Research median of 33.08. The forward P/E on file is 16.66. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.17. Measured against sales, the shares trade at 4.27 times revenue. On price-to-sales that is 14.36% below the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.63. Annualized volatility over the trailing 10 years is 27.01%. Over the trailing twelve months the price has returned −6.76%. Measured over 10 years, that is +5.17% a year compounded.

Growth & Income

Shareholders receive a dividend, yielding 0.8% on the latest price. The indicated annual rate is $0.35 a share. The ex-dividend date on file is July 7, 2026. Dividends are recorded for 4 calendar years; 2026 shows 1 payments totalling $0.35 a share. The year before, 2025, totalled $0.25 a share.

Across the complete calendar years on file, 2020 returned +56.36% and 2023 returned −12.91%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is −2.46% year to date.

Peer Comparison

Qiagen N.V. (QGEN) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Qiagen N.V. QGEN $8.98B 22.1
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Qiagen N.V. trades at a P/E of 22.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Qiagen N.V.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Visit website →